

|   |  |  |  |  |  |                                      |  |
|---|--|--|--|--|--|--------------------------------------|--|
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) |  |  |  | Attorney Docket No.<br><b>056291-5174-US</b> |  | Application No.<br><b>10/505,231</b> |  |
| PTO Form 1449<br>August 4, 2006   |  |  |  | Applicants: <b>GELLERT et al.</b>            |  |                                      |  |
| Filing Date: <b>August 19, 2004</b>   |  |  |  | Group Art Unit: <b>1615</b>                  |  |                                      |  |

**U.S. PATENT DOCUMENTS**

| Initial |    | Document No. | Date               | Name               | Class | Sub-Class | Filing Date      |
|---------|----|--------------|--------------------|--------------------|-------|-----------|------------------|
| JDA     | 1. | 20050209229  | September 22, 2005 | Gilday et al.      | 514   | 234.2     | May 23, 2005     |
| JDA     | 2. | 20020177601  | November 28, 2002  | Himmelsbach et al. | 514   | 266.2     | August 23, 2001  |
| JDA     | 3. | 5,610,193    | March 11, 1997     | Al-Razzak et al.   | 514   | 616       | May 22, 1996     |
| JDA     | 4. | 4,178,376    | December 11, 1979  | Higuchi et al.     | 514   | 311       | January 21, 1977 |
| JDA     | 5. | 3,608,063    | September 21, 1971 | Banker             | 424   | 485       | August 15, 1969  |

**FOREIGN PATENT DOCUMENTS**

|     |     | Document No. | Date               | Country       | Class | Sub-Class | Translation |
|-----|-----|--------------|--------------------|---------------|-------|-----------|-------------|
| JDA | 6.  | DE 3233764   | May 7, 1987        | Germany       |       |           | Yes         |
|     | 7.  | EP 1027888   | August 16, 2000    | EPA           |       |           |             |
|     | 8.  | EP 103387    | March 21, 1984     | EPA           |       |           |             |
|     | 9.  | EP 640341    | March 1, 1995      | EPA           |       |           |             |
|     | 10. | GB 1278816   | June 21, 1972      | Great Britain |       |           |             |
|     | 11. | JP 05-255066 | October 5, 1993    | Japan         |       |           | Yes         |
|     | 12. | JP 62-123117 | June 4, 1987       | Japan         |       |           | Yes         |
|     | 13. | WO 95/09614  | April 13, 1995     | WIPO          |       |           |             |
|     | 14. | WO 97/02017  | January 23, 1997   | WIPO          |       |           |             |
|     | 15. | WO 98/55148  | December 10, 1998  | WIPO          |       |           |             |
|     | 16. | WO 00/16776  | March 30, 2000     | WIPO          |       |           | Yes         |
|     | 17. | WO 00/55141  | September 21, 2000 | WIPO          |       |           |             |
|     | 18. | WO 00/56338  | September 28, 2000 | WIPO          |       |           |             |
|     | 19. | WO 02/06834  | January 24, 2002   | WIPO          |       |           |             |
|     | 20. | WO 02/64132  | August 22, 2002    | WIPO          |       |           |             |
|     | 21. | WO 02/65834  | August 29, 2002    | WIPO          |       |           |             |
|     | 22. | WO 03/017940 | March 6, 2003      | WIPO          |       |           |             |
|     | 23. | WO 03/024426 | March 27, 2003     | WIPO          |       |           |             |
|     | 24. | WO 03/024429 | March 27, 2003     | WIPO          |       |           |             |
|     | 25. | WO 03/024430 | March 27, 2003     | WIPO          |       |           |             |
| JDA | 26. | WO 03/072139 | September 4, 2003  | WIPO          |       |           |             |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

|     |     |   |
|-----|-----|---|
| JDA | 27. | Baselga et al. "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types" J Clin Oncol. 20(21): 4292-4302 (2002) |
| JDA | 28. | Berger et al. "Supersaturation of sulfates in electrodialysis" Ind. Eng. Chem., Process Design Develop. 1: 229-236 (1962) Abstract  |
| JDA | 29. | Brewster et al. "A Novel Cyclodextrin-containing Glass Thermoplastic System (GTS) for Formulating Poorly Water Soluble Drug Candidates: Preclinical and Clinical Results" Journal of Inclusion Phenomena and Macrocyclic Chemistry 44(1-4): 35-38 (2002)    |

|          |                  |                 |            |
|----------|------------------|-----------------|------------|
| Examiner | /James Anderson/ | Date Considered | 02/20/2007 |
|----------|------------------|-----------------|------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|  |     |   |      |  |       |                               |             |
|--|-----|---|------|--|-------|-------------------------------|-------------|
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary)<br><br>PTO Form 1449<br>August 4, 2006   |     |   |      | Attorney Docket No.<br>056291-5174-US    |       | Application No.<br>10/505,231 |             |
|  |     |   |      | Applicants: <b>GELLERT <i>et al.</i></b> |       |                               |             |
|  |     |   |      | Filing Date: <b>August 19, 2004</b>      |       | Group Art Unit: <b>1615</b>   |             |
| <b>U.S. PATENT DOCUMENTS</b>   |     |   |      |  |       |                               |             |
| Initial  |     | Document No.  | Date | Name                                     | Class | Sub-Class                     | Filing Date |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
| <b>FOREIGN PATENT DOCUMENTS</b>  |     |   |      |  |       |                               |             |
|  |     | Document No.  | Date | Country                                  | Class | Sub-Class                     | Translation |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
| <b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>  |     |   |      |  |       |                               |             |
| JDA  | 30. | Capello et al. "Percutaneous penetration of Ibuprofen from supersaturated solutions" Acta Technologiae et Legis Medicamenti XIII(1): 25-35 (2002) (Translation enclosed)  |      |  |       |                               |             |
| JDA  | 31. | Espinoza "Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets" Int J Pharm. 201(2):165-173 (2000)  |      |  |       |                               |             |
| JDA  | 32. | McKillop et al. "Cytochrome P450-dependent metabolism of gefitinib" Xenobiotica 35(1): 39-50 (2005)   |      |  |       |                               |             |
| JDA  | 33. | McKillop et al. "Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man" Xenobiotica 34(10): 917-934 (2004)   |      |  |       |                               |             |
| JDA  | 34. | Munday "Film coated pellets containing verapamil hydrochloride: enhanced dissolution into neutral medium" Drug Development and Industrial Pharmacy 29(5): 575-583 (2003)  |      |  |       |                               |             |
| JDA  | 35. | N Magné et al. "Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer" British Journal of Cancer 86: 819-827 (2002)   |      |  |       |                               |             |
| JDA  | 36. | Nakagawa et al. "Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors" Ann Oncol. 14(6): 922-930 (2003) |      |  |       |                               |             |
| JDA  | 37. | Neiman et al. "Separation of a highly dispersed fraction in supersaturated solutions during formation of calcium sulfate precipitates" Kolloid. Zh. 35(4): 781-783 (1973) Abstract  |      |  |       |                               |             |
| JDA  | 38. | Venkatesh "Development of controlled-release SK&F 82526-J buffer bead formulations with tartaric acid as the buffer" Pharm Dev Technol. 3(4):477-485 (1998)   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
|  |     |   |      |  |       |                               |             |
| Examiner   |     | /James Anderson/  |      | Date Considered 02/20/2007               |       |                               |             |
| Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |     |   |      |  |       |                               |             |